NICE rejects AstraZeneca's Faslodex.
M2 EQUITYBITES-February 2, 2018-NICE rejects AstraZeneca's Faslodex
(C)2018 M2 COMMUNICATIONS http://www.m2.com
In its final guidelines, the National Institute for Health and Care Excellence (NICE) has rejected AstraZeneca's (LON: AZN) Faslodex (fulvestrant) as a treatment option for certain patients with breast cancer, Pharma Times reported on Friday.
The watchdog did not recommend the drug, as per the marketing authorisation, as a treatment for locally advanced or metastatic oestrogen-receptor positive breast cancer in postmenopausal women who have not previously had endocrine therapy.
Data from the Phase III FLACON trial demonstrated median progression-free survival (PFS) as being significantly longer with Faslodex when compared to anastrozole, with 16.6 months and 13.8 months, respectively.
NICE noted, however, the final data on the drug's impact on overall survival would not be expected until the end of next year. This made it unclear as to whether it would extend overall survival compared to the current standard of treatment with aromatase inhibitors. The body concluded, therefore, that the cost-effectiveness of the drug compared to existing treatments was "highly uncertain".
Faslodex was approved for first-line use in breast cancer patients in Europe in July 2017.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Feb 2, 2018|
|Previous Article:||Puma Biotechnology and CANbridge Life Sciences enter exclusive licensing agreement.|
|Next Article:||Tera Ventures to raise second seed fund.|